[Attractiveness of France for international clinical trials in 2012: 6(th) survey assessed by Leem (French association of pharmaceutical companies)]. / État des lieux 2012 de l'attractivité de la France pour la recherche clinique internationale : 6(e) enquête du Leem.
Therapie
; 68(1): 1-18, 2013.
Article
em Fr
| MEDLINE
| ID: mdl-23484655
Since 2002, the Leem (French Association of Pharmaceutical Companies) has conducted a survey every two years to update the attractiveness of France for international clinical trials. Thirty companies (68% of the French market) have participated in this 6(th) survey which involved 79 countries, a greater number of Phases I/II, II and III studies (420 versus 352 in 2010), a relatively stable number of included patients (246,895 versus 249,704 in 2010) and a greater number of centers (32,965 versus 24,337 in 2010). The evolution of time-lines for the go-ahead by French Authorities is heterogeneous (shorter time-lines by the French National Agency of Drug and Health Products Safety [ANSM] but longer time-lines by Research Ethics Comittees [CPP]). The time-lines for first hospital contracts remain stable. France ranks at an average position among European countries in regards to quantitative and qualitative data, and its state-of-art in early stages is still recognized. Its good performance in oncology and orphan diseases are major assets of competitiveness.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ensaios Clínicos Fase III como Assunto
/
Ensaios Clínicos Fase II como Assunto
/
Ensaios Clínicos Fase I como Assunto
/
Indústria Farmacêutica
Tipo de estudo:
Qualitative_research
/
Risk_factors_studies
Aspecto:
Ethics
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
Fr
Revista:
Therapie
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
França
País de publicação:
França